ANPEP (Alanyl Aminopeptidase, Membrane)

Compared with non-APL-AML patients, APL patients (PML-RARα (S-type) and PML-RARα (L-type)) exhibit unique immunophenotypic changes. The expression frequencies of CD56, CD2, CD34, and CD200 in leukemia cells are significantly correlated with the OS of APL patients, and the high expression of these indicators before treatment may be an adverse prognostic factor for APL patients.

By targeting nucleic acids, FLT3 or CD33, several FDA-approved NPs and NPDs (i.e., cytarabine, anthracyclines, midostaurin, melphalan and calicheamicin linked to anti-CD33) are the major agents of upfront treatment of AML. This review summarizes the current state of the art, and provides a summary of selected NPs/NPDs which are either entering or have been investigated in preclinical and clinical trials, alone or in combination with current chemotherapy. With multifaceted actions, these biomolecules may target all hallmarks of AML, including multidrug resistance and deregulated metabolism.

Adding ANPEP and PIGR to a plasma biomarker panel of CA19-9 and THBS2 enhances the detection of early-stage PDAC when comparing cancer versus healthy or nonmalignant DC. Given the concordance of our data in two retrospective phase II studies, assessments in prediagnostic cases are warranted.

Loss- and gain-of-function experiments further revealed that CD13 enhances cancer cell seeding in the brain microenvironment. Together, these findings establish CD13 as an important mediator of brain metastatic colonization and a potential therapeutic target to prevent or delay disease progression.

This study initially identified two cuproptosis-related molecules based on the expression patterns of cuproptosis-related genes. In addition, we developed a new cuproptosisrelated molecular signature with great predictive performance for BCRFS and tumor immune environment using six DERRGs (including CALML5, MMP11, UBE2C, ANPEP, TMEM59L, COMP). These findings would be conducive to a deeper cognition of the potential mechanism of cuproptosis of PCa.

The study demonstrated a high ratio of abnormal CD marker expression in AL cases, aligning previous data from various area around the world. Identifying aberrant antigen expression patterns through immunophenotyping aids in diagnosing leukemia and distinguishing neoplastic cells from normal hematopoietic precursors.

The uniqueness of the case is the presence of an additional population of bonafide promonocytes in an otherwise typical case of Philadelphia-positive B-ALL expressing CD13 and CD33. This case underscores the importance of morphology and cytochemistry in detecting and confirming minor blast populations, which may manifest as the dominant or the only clone at relapse.

We looked at levels of a protein called aminopeptidase N (ANPEP) in prostate tumors using information from large databases. We found that ANPEP is linked to markers that indicate more aggressive disease and that higher ANPEP levels are associated with more favorable treatment outcomes.

This activates phosphatidylinositol-4-phosphate-5-kinase (PI5K) to increase local phosphatidylinositol 4,5-bisphosphate (PI(4,5)P2) levels, promoting actin-polymerization and membrane protrusion. Therefore, CD13 is a novel molecular PIP regulator, modulating signal transduction and downstream cellular processes, including actin cytoskeleton dynamics and membrane organization to facilitate intercellular communication.

CD97, CD73, CD86, and CD58 are the best amongst newer markers in B-ALL MRD assessment. Our findings support integrating these into MRD panels to enhance post-therapy MRD detection, thus improving prognostication and guiding treatment decisions.

This study proposes a panel of potential prognostic biomarkers for the treatment of ovarian cancer patients, particularly by leveraging TGFB2-dependent mRNA expression as a significant biomarker, alongside four additional TGFB2-independent prognostic markers, for patients undergoing Taxol-based therapies. Future prospective clinical trials will be required to validate these prognostic markers.

A review of published ZMYND11::MBTD1 leukemias (n = 5) found immunophenotypes highly consistent with MNKPL, suggesting prior misclassification. These findings support ZMYND11::MBTD1 as a recurrent lesion in MNKPL and a practical aid to diagnosis and treatment selection.